Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 8/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21335487 | 0.82 | GSK3A (0.36) | GSK3AGSK3BGRIN2BALDH1A1LMNA | |
| SCHEMBL17446263 | 0.77 | GSK3A (0.44) | GSK3AGSK3BPKMALDH1A1LMNA | |
| SCHEMBL17446280 | 0.73 | GSK3A (0.51) | GSK3AGSK3BPKMALDH1A1LMNA | |
| SCHEMBL17446134 | 0.69 | GSK3A (0.60) | GSK3AGSK3BPKMALDH1A1MAPT | |
| SCHEMBL17446109 | 0.68 | GSK3A (0.55) | GSK3AGSK3BPKMALDH1A1LMNA | |
| SCHEMBL11387505 | 0.68 | GSK3A (0.52) | GSK3AGSK3BPKMGRIN2BALDH1A1 | |
| SCHEMBL17446262 | 0.68 | GSK3A (0.59) | GSK3AGSK3BPKMALDH1A1LMNA | |
| SCHEMBL17450498 | 0.67 | GSK3A (0.72) | GSK3AGSK3BPKM | |
| SCHEMBL11108434 | 0.67 | GSK3A (0.57) | GSK3AGSK3BPKMALDH1A1LMNA | |
| SCHEMBL17446266 | 0.66 | GSK3A (0.74) | GSK3AGSK3BPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2019-09-10 | — | — | US | disclosed |
| US-10392381-B2 | Prevention and treatment of non-alcoholic fatty liver disease | OHIO UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170210737-A1 | IMIDAZOLE AND THIAZOLE COMPOSITIONS FOR MODIFYING BIOLOGICAL SIGNALING | OHIO UNIVERSITY (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170202818-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | OHIO UNIVERSITY (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170202818-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | OHIO UNIVERSITY (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170196845-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | OHIO UNIVERSITY (US) | 2017-07-13 | — | — | US | disclosed |
| WO-2016010609-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | OHIO UNIVERSITY (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016010611-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | OHIO UNIVERSITY (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392381-B2 | Prevention and treatment of non-alcoholic fatty liver disease | FABP1, LIPC, SLC10A1 | GSK3A 1343/4885GSK3B 1342/4885PKM 569/4885 |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | GSK3A 1263/4885GSK3B 725/4885PKM 830/4885 |
| US-20170196845-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | FABP1, LIPC, SLC10A1 | GSK3A 1343/4885GSK3B 1342/4885PKM 569/4885 |
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | GSK3A 1251/4885GSK3B 724/4885PKM 843/4885 |
| US-20170210737-A1 | IMIDAZOLE AND THIAZOLE COMPOSITIONS FOR MODIFYING BIOLOGICAL SIGNALING | FGFR1, TYRO3, STAT6 | GSK3A 1332/4885GSK3B 799/4885PKM 813/4885 |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | FGFR1, TYRO3, STAT6 | GSK3A 1332/4885GSK3B 799/4885PKM 813/4885 |
| US-20170202818-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | GSK3B, GSK3A, GSKIP | GSK3A 2/4885GSK3B 1/4885PKM 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.